MENLO PARK, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that Karin Eastham has been named the new chair of the Personalis board of directors effective Personalis Annual Meeting of Shareholders May 17, 2022 Ms. Eastham joined the Personalis Board of Directors in 2019 and chaired its Audit and Nominating and Corporate Governance Committees. Ms. Eastham previously served on the board of Illumina, from 2004 to 2019. During this time, Illumina acquired Solexa and became the world leader in DNA sequencing, and also launched multiple initiatives enabling its customers to leverage technology in diagnostics including oncology, NIPT, infectious diseases and many inherited genetic diseases. Since 2012, Ms. Eastham has also served on the board of Veracyte, an advanced genomic diagnostics company. During this period, Veracyte’s annual revenue grew from approximately $11.6 million to over $200 million.
“I am honored to be chosen as the next Chair of the Personalis Board of Directors at this exciting time in the company’s growth,” said Ms. Eastham. “I look forward to working closely with my fellow board members and the company’s leadership team to help realize Personalis’ vision of pharmaceutical and diagnostics companies that synergistically benefit from a common base of increasingly advanced technologies.
“Karin’s extensive leadership and operating experience, as well as her proven track record as a director of public life sciences companies, with a particular focus on cancer patients, uniquely positions her to serve as the next Personalis Board Chair,” said John West, CEO and Co-Founder. “This experience will be particularly relevant to Personalis as we grow our oncology diagnostics business.”
Jonathan MacQuitty, Ph.D., who led the initiative for this transition, has decided not to stand again at the next annual meeting. “It has been an honor to chair Personalis’ Board of Directors,” said Dr. MacQuitty. “I am extremely proud of the technology and intellectual property that Personalis has developed over the past 11 years, particularly in neoantigen-based biomarkers for immuno-oncology, and its technology leadership in cancer surveillance. based on tumors. These have led to substantial and rapidly growing business with major oncology-focused pharmaceutical companies. We have understood for some time that this advanced technology could also serve as a basis for complementary activity in diagnostics. This was part of my motivation to help recruit Karin to our Board of Directors in 2019. Over the next three years, she has come to know the management team well and supports the growing focus by the team on the creation of a second company focused on diagnostics. I have recommended that the role of chair now transition to a board member with strong business experience in NGS diagnostics. I will continue to support the company as an outside strategic advisor and look forward to its continued success. »
“It has been a privilege to work closely with Jonathan since founding Personalis over a decade ago,” said Mr. West. “On behalf of our Board of Directors, the Company and shareholders, and personally, I would like to thank Jonathan for the invaluable contributions he has made as Chairman, from the founding of the Company until today. today. I look forward to his continued involvement and support.
Also effective at the company’s annual meeting, the Personalis Board of Directors appointed Olivia Bloom as Chair of the Audit Committee of the Personalis Board of Directors and Blaine Bowman as Chair of the Compensation Committee. of Personalis’ Board of Directors. Ms. Eastham will continue to chair the Nominating and Corporate Governance Committee in addition to her new role as Chair of the Board.
Personalis, Inc. is a leader in advanced cancer genomics to enable the next generation of precision cancer therapies and diagnostics. the Personalis NeXT platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical and clinician customers with information on all of the approximately 20,000 human genes, as well as the immune system, from a single sample . To enable cancer sequencing, Personalis Clinical laboratory was built with a focus on clinical precision, quality, big data, scale and efficiency. The laboratory is aligned with GxP as well as the 1988 Clinical Laboratory Improvement Amendments and is accredited by the College of American Pathologists. For more information, visit the Personalized website and follow Personalis on LinkedIn and Twitter.
All statements in this press release that are not historical are “forward-looking statements” within the meaning of United States securities laws, including statements relating to the attributes or benefits of the NeXT Platform, business opportunities, leadership, mission, vision, plans or expectations or other future events. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis’ filings with the United States Securities and Exchange Commission, including Personalis’ most recent reports on Forms 8-K, 10-K and 10-Q, the company’s registration statement on Form S-3 filed on December 30, 2020 and the company’s prospectus supplement filed on January 3, 2022, and include those listed under the heading “Risk Factors” . Personalis disclaims any obligation to update these forward-looking statements.